Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex Reversal of Deep NMB in Chinese and Caucasian Subjects
NCT00826176Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2010
- Primary completion
- Aug 2010
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
A Phase 3 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Merck & Co.. Started Jan 2010; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT00826176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00826176.